Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury
September 7th, 2018
8.6K views
Here, we present the modifications necessary to a well characterized and commonly used small animal ferric chloride-induced (FeCl3) carotid artery injury model for use in a large animal vascular injury model. The resulting model can be utilized for pre-clinical trial assessment of both prophylactic and thrombolytic pharmacological and mechanical interventions.
Overview
This article presents a modified ferric chloride-induced carotid artery injury model for large animals, facilitating pre-clinical trial assessments. The model enables the evaluation of both prophylactic and thrombolytic interventions.
Key Study Components
Area of Science
- Thrombosis research
- Vascular injury models
- Pre-clinical trials
Background
- Thrombosis is a critical area of study in vascular biology.
- Large animal models provide physiological relevance to human conditions.
- Monitoring physiological parameters is essential for understanding treatment effects.
- Existing models may not adequately represent human responses.
Purpose of Study
- To adapt a small animal model for use in larger species.
- To facilitate the study of thrombosis and related disorders.
- To improve the translational potential of therapeutic interventions.
Methods Used
- Induction of carotid artery injury using ferric chloride.
- Monitoring of physiological parameters such as blood count and platelet function.
- Use of angiography for real-time observation.
- Histological analysis and serial blood sampling throughout the procedure.
Main Results
- The modified model is reproducible and allows for detailed monitoring.
- Physiological parameters relevant to humans can be assessed effectively.
- Histological data can be captured to evaluate injury and healing.
- The model supports the study of thrombus formation and resolution.
Conclusions
- This model enhances the understanding of thrombosis in a relevant context.
- It provides a platform for testing new therapeutic strategies.
- The approach may lead to better outcomes in clinical settings.
Frequently Asked Questions
What is the significance of using a large animal model?
Large animal models allow for the monitoring of physiological parameters that are more relevant to human conditions, improving translational research.
How does this model improve upon existing methods?
The modified model is reproducible and allows for comprehensive monitoring and analysis of thrombosis and vascular injury.
What are the main advantages of this technique?
Advantages include the ability to monitor physiological responses, capture histological data, and perform serial blood sampling.
What types of interventions can be tested with this model?
Both prophylactic and thrombolytic pharmacological and mechanical interventions can be assessed using this model.
What physiological parameters can be monitored?
Parameters such as complete blood count and platelet function can be monitored throughout the procedure.
Executive Industry Relevance
This large animal thrombosis model addresses a critical gap in preclinical cardiovascular drug development by enabling physiologically relevant assessment of prophylactic and thrombolytic agents. The canine model supports monitoring of human-relevant parameters such as complete blood count and platelet function, improving translational confidence. By integrating angiography, histology, serial blood sampling, and MRI, the protocol provides multimodal endpoints for de-risking target validation and lead identification in thrombosis research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses in a physiologically relevant large animal system.
- Operational Value: Supports biological de-risking through multimodal verification of thrombus formation and resolution.
- Predictive Value: Facilitates target confidence by linking vascular injury to downstream thromboembolic events via MRI and histology.
Screening & Assay Development
- Scientific Value: Provides a reproducible platform for quantitative assessment of compound effects on thrombosis.
- Operational Value: Standardizes vascular injury induction and monitoring via angiography and flow probes.
- Scalability Value: Supports serial blood sampling and imaging time points for dose-response and pharmacokinetic profiling.
Translational & Preclinical Research
- Scientific Value: Bridges discovery to preclinical validation by modeling carotid artery thrombosis and cerebral hemorrhage.
- Operational Value: Enables continuity of assessment from acute injury to downstream thromboembolic outcomes.
- Risk Mitigation: Supports go/no-go decisions by quantifying recanalization, hemorrhage volume, and stroke burden.
Pipeline & Workflow Integration
The model fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing, particularly for antithrombotic and thrombolytic candidates.
- Discovery Biology: Supports hypothesis testing of thrombotic pathways and target modulation in a disease-relevant system.
- Screening: Delivers assay readiness through standardized ferric chloride injury and real-time angiographic verification of occlusion.
- Analytics: Generates quantitative dependent variables including blood velocity, clot length, MRI-derived stroke/hemorrhage volume, and histological recanalization status.
- Translational Research: Connects vascular injury to cerebral ischemic outcomes, enabling biomarker alignment and pathophysiological continuity.
- Enterprise Reuse: Establishes a reusable large animal platform for iterative testing of prophylactic and thrombolytic interventions across programs.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through mechanistic de-risking of thrombosis pathways.
- Operational Value: Reproducibility, standardization, and multimodal data capture across physiology, imaging, and histology.
- Strategic Value: Improved go/no-go decisions, reduced late-stage biological risk, and capital efficiency in cardiovascular programs.
- Portfolio Impact: Risk-adjusted prioritization based on translatable efficacy and safety signals in a human-relevant model.
Implementation Considerations
- Expertise in vascular surgery, angiography, and anesthesia management in large animals.
- Access to fluoroscopy, MRI, and histological processing infrastructure.
- Standardization of ferric chloride application, flow probe placement, and thrombus stabilization timing.
- Adaptation considerations for varying canine sizes and vascular anatomy.
- Practical limitations including procedural duration (8–10 hours), radiation safety, and contrast agent allergy risks.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in this model?
Null hypothesis testing enables statistical evaluation of whether observed thrombus formation or recanalization differs significantly from baseline, supporting objective target validation decisions.
How does independent variable isolation fit the discovery pipeline?
Isolating the ferric chloride-induced injury as the independent variable allows researchers to attribute changes in thrombus characteristics or blood flow specifically to the intervention being tested.
What quantitative dependent variable measurements enable target assessment?
Measurements such as percent re-perfusion, clot length, MRI-derived stroke volume, and histological recanalization status provide quantifiable endpoints for evaluating therapeutic effects.
Why do replication requirements matter for cross-functional collaboration?
Reproducibility of the thrombosis model ensures consistent data across sites and teams, enabling reliable comparison of compound effects in multidisciplinary drug development efforts.
What statistical analysis capabilities are required before implementation?
Teams require the ability to perform parametric or non-parametric tests on longitudinal physiological, imaging, and histological data to determine significant differences between control and treatment groups.
